CN1184321C - 腺病毒介导的基因治疗 - Google Patents

腺病毒介导的基因治疗 Download PDF

Info

Publication number
CN1184321C
CN1184321C CNB998129305A CN99812930A CN1184321C CN 1184321 C CN1184321 C CN 1184321C CN B998129305 A CNB998129305 A CN B998129305A CN 99812930 A CN99812930 A CN 99812930A CN 1184321 C CN1184321 C CN 1184321C
Authority
CN
China
Prior art keywords
adenovirus
tumor
patients
gene
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998129305A
Other languages
English (en)
Chinese (zh)
Other versions
CN1325450A (zh
Inventor
S·耶拉－赫图亚拉
A－M·桑德迈尔
S·洛马斯
M·瓦帕拉蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1184321(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of CN1325450A publication Critical patent/CN1325450A/zh
Application granted granted Critical
Publication of CN1184321C publication Critical patent/CN1184321C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB998129305A 1998-11-06 1999-11-05 腺病毒介导的基因治疗 Expired - Fee Related CN1184321C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9824437.9 1998-11-06
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy

Publications (2)

Publication Number Publication Date
CN1325450A CN1325450A (zh) 2001-12-05
CN1184321C true CN1184321C (zh) 2005-01-12

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998129305A Expired - Fee Related CN1184321C (zh) 1998-11-06 1999-11-05 腺病毒介导的基因治疗

Country Status (18)

Country Link
US (1) US6579855B1 (https=)
EP (1) EP1135513B2 (https=)
JP (1) JP4733833B2 (https=)
KR (1) KR20020013473A (https=)
CN (1) CN1184321C (https=)
AT (1) ATE341639T1 (https=)
AU (1) AU749451B2 (https=)
CA (1) CA2348624C (https=)
CY (1) CY1106198T1 (https=)
DE (1) DE69933468T3 (https=)
DK (1) DK1135513T4 (https=)
ES (1) ES2273521T5 (https=)
GB (1) GB9824437D0 (https=)
HU (1) HUP0104046A3 (https=)
NO (1) NO330776B1 (https=)
PL (1) PL193076B1 (https=)
PT (1) PT1135513E (https=)
WO (1) WO2000028059A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
CA2863964C (en) 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
WO2015021443A1 (en) 2013-08-08 2015-02-12 Global Bio Therapeutics Usa, Inc. Clamp device for minimally invasive procedures and uses thereof
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
MX2022014239A (es) 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
TW202334223A (zh) 2021-11-11 2023-09-01 美商再生元醫藥公司 Ｃｄ２０－ｐｄ１結合分子及其使用方法
EP4649088A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4649092A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
EP4709756A1 (en) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
ES2273521T3 (es) 2007-05-01
GB9824437D0 (en) 1999-01-06
KR20020013473A (ko) 2002-02-20
DK1135513T4 (da) 2011-11-21
CA2348624A1 (en) 2000-05-18
EP1135513A1 (en) 2001-09-26
WO2000028059A1 (en) 2000-05-18
US6579855B1 (en) 2003-06-17
DE69933468T3 (de) 2012-01-19
CN1325450A (zh) 2001-12-05
ATE341639T1 (de) 2006-10-15
ES2273521T5 (es) 2011-12-28
DE69933468D1 (de) 2006-11-16
HUP0104046A3 (en) 2003-09-29
CY1106198T1 (el) 2011-06-08
DE69933468T2 (de) 2007-01-11
NO20012220L (no) 2001-05-04
PT1135513E (pt) 2006-12-29
NO20012220D0 (no) 2001-05-04
NO330776B1 (no) 2011-07-11
PL193076B1 (pl) 2007-01-31
HUP0104046A2 (hu) 2002-01-28
CA2348624C (en) 2012-07-31
JP4733833B2 (ja) 2011-07-27
EP1135513B1 (en) 2006-10-04
DK1135513T3 (da) 2006-11-27
JP2002529097A (ja) 2002-09-10
AU749451B2 (en) 2002-06-27
EP1135513B2 (en) 2011-08-10
AU1385100A (en) 2000-05-29
PL349489A1 (en) 2002-07-29

Similar Documents

Publication Publication Date Title
CN1184321C (zh) 腺病毒介导的基因治疗
JP4213201B2 (ja) 固型腫瘍、乳頭腫および疣贅の遺伝子治療
US12241079B2 (en) Compositions and methods for hemoglobin production
Goodman et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies
AU2018301504B2 (en) Method for managing pain
CA2549000A1 (en) Method for treating neurological disorders
US20200023077A1 (en) Treatment of neuropathy with dna constructs expressing igf-1 isoforms
EP4347791A1 (en) Drug for genetic and gene-cell-based therapy
WO2016033318A1 (en) Sprr1a as a genetic target for treating neurodegenerative diseases
US20230295658A1 (en) Compositions and methods for in vivo gene transfer
HUP0104032A2 (hu) Új rendszer transzgén kifejeződés szabályozására
JP2023510907A (ja) キメラデコイによる炎症抑制の延長及び／又は脊椎痛治療の延長に関連する方法及び組成物
CA2367648A1 (en) Recombinant adeno-associated virus transfer of genes affecting demyelination
WO2025084951A1 (en) Recombinant genetic construct, adeno-associated virus for the treatment of metachromatic leukodystrophy
MXPA01004410A (es) Terapia de gen mediada por adenovirus
JP2005336081A (ja) Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
WO2026062177A1 (en) Variants of sirtuin 6 for the treatment of muscular diseases
WO2024178364A1 (en) Gene therapy for treatment of pain
WO2026087567A1 (en) Transcriptional regulatory elements for cardiac-specific gene expression
WO2024100176A1 (en) Controlled gene therapy of ocular diseases
US8431119B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050112

Termination date: 20141105

EXPY Termination of patent right or utility model